A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Leukemia - CALGB-10502
Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502 Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008 Abstract - Primary - Primary - Lymphoma - CALGB-50502
Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism Blum, K. A. , Jung, S.-H. , Johnson, J. L. , Lin, T. S. , Hsi, E. D. ... - - Ann Oncol - 2010 Manuscript - Primary - Primary - Lymphoma - CALGB-50502
A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402 Czuczman, M. S. , Johnson, J. L. , Jung, S. ... - - Ann. Oncol. - 2008 Abstract - Primary - Primary - Lymphoma - CALGB-50402
FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R] Czuczman, M. S. , Leonard, J. P. , Johnson, J. L. , Jung, S.-H. ... - - Blood - 2008 Abstract - Secondary - Primary - Lymphoma - CALGB-50402
Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20) Grant, B. , Leonard, J. P. , Johnson, J. L. , Kostakoglu, L. , Hsi, E. ... - - Blood - 2010 Abstract - Primary - Primary - Lymphoma - CALGB-50701
Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study Hsi, E. D. , Said, J. , Johnson, J. L. , Jung, S. , Lai, R. , Jones, D. ... - ASH - Blood - 2008 Abstract - Secondary - Primary - Correl Sci NOS - CALGB-50103
A randomized phase II trial of maintenance vs consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma (MCL): CALGB 50403 Kaplan, L. D. , Jung, S. , Johnson, J. L. , Linker, C. , Byrd, J. C. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Preliminary - Lymphoma - CALGB-50403
Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone? Kostakoglu, L. , Schoder, H. , Hall, N. C. , Straus, D. J. ... - ASH - ASH Annual Meeting Abstracts - 2011 Abstract - Secondary - Primary - Lymphoma - CALGB-50203
Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results Kostakoglu, L. , Straus, D. J. , Schoder, H. , Lacasce, A. S. ... - ASH - ASH Annual Meeting Abstracts - 2008 Abstract - Secondary-not-in-original - Primary - Lymphoma - CALGB-50203
CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. Leonard, J. , Jung, S.-H. , Johnson, J. L. , Bartlett, N. L. ... - - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Lymphoma - CALGB-50401
A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis. Morrison, V. A. , Johnson, J. L. , Jung, S. , Leonard, J. P. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Preliminary - Lymphoma - CALGB-50501
Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002 Rizzieri, D. A. , Johnson, J. L. , Byrd, J. C. , Lozanski, G. ... - - Blood - 2010 Abstract - Primary - Primary - Leukemia - CALGB-10002
BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance) Rubenstein, J. L. , Hsi, E. D. , Johnson, J. L. , Jung, S.-H. ... - ASH - ASH Annual Meeting Abstracts - 2012 Abstract - Secondary - Primary - Lymphoma - CALGB-50202
Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202) Rubenstein, J. L. , Hsi, E. D. , Johnson, J. L. , Jung, S.-H. ... - - J. Clin. Oncol. - 2013 Manuscript - Primary - Primary - Lymphoma - CALGB-50202
Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202 Rubenstein, J. L. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2010 Abstract - Primary - Primary - Lymphoma - CALGB-50202
Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma (HL): Final results of CALGB 50602 Smith, S. M. , Bartlett, N. L. , Johnson, J. L. , Jung, S. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Lymphoma - CALGB-50602
Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen excluding bleomycin for the treatment of early stage Hodgkin Lymphoma (HL): Results of CALGB 50203 Straus, D. J. , Lacasce, A. S. , Juweid, M. E. , Kostakoglu, L. ... - - Blood - 2007 Abstract - Primary - Primary - Lymphoma - CALGB-50203
Multi-center study of dose-adjusted epoch-r in untreated diffuse large b-cell lymphoma: CALGB 50103 Wilson, W. H. , Zelenetz, A. D. , Niedzwiecki, D. , Hurd, D. D. ... - - Ann. Oncol. - 2008 Abstract - Primary - Primary - Lymphoma - CALGB-50103
